Advancing Killer Cell Immunotherapy with Mark Frohlich

Season 1 Episode 7:

In this episode, we talk with Dr. Mark Frohlich, CEO of Indapta Therapeutics, a biotech company working to make cancer treatment safer, more effective, and more accessible. Indapta is developing natural killer (NK) cell therapies—an emerging form of immunotherapy that uses the body’s own immune system to fight disease.

Mark shares his path from clinical oncology to biotech leadership and explains why NK cells are generating excitement as a next-generation alternative to existing treatments like CAR-T. We discuss how Indapta’s work could help more patients benefit from cell therapy, what it takes to move from lab research to human trials, and how strong partnerships—including early support from Michigan State University—are fueling the company’s progress.

Host: David Washburn
Guest: Dr. Mark Frohlich, CEO of Indapta Therapeutics

Producers: Jenna McNamara and Doug Snitgen

Music: "Devil on Your Shoulder" by Will Harrison, licensed via Epidemic Sound



Stay connected with the MSU Research Foundation by following us on LinkedIn or subscribing to our email newsletters.